330 related articles for article (PubMed ID: 34193233)
1. Interplay between Epstein-Barr virus infection and environmental xenobiotic exposure in cancer.
Aguayo F; Boccardo E; Corvalán A; Calaf GM; Blanco R
Infect Agent Cancer; 2021 Jun; 16(1):50. PubMed ID: 34193233
[TBL] [Abstract][Full Text] [Related]
2. miR-18a reactivates the Epstein-Barr virus through defective DNA damage response and promotes genomic instability in EBV-associated lymphomas.
Cao P; Zhang M; Wang L; Sai B; Tang J; Luo Z; Shuai C; Zhang L; Li Z; Wang Y; Li G; Xiang J
BMC Cancer; 2018 Dec; 18(1):1293. PubMed ID: 30594162
[TBL] [Abstract][Full Text] [Related]
3. Efficient Translation of Epstein-Barr Virus (EBV) DNA Polymerase Contributes to the Enhanced Lytic Replication Phenotype of M81 EBV.
Church TM; Verma D; Thompson J; Swaminathan S
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263273
[TBL] [Abstract][Full Text] [Related]
4. Nascent Transcriptomics Reveal Cellular Prolytic Factors Upregulated Upstream of the Latent-to-Lytic Switch Protein of Epstein-Barr Virus.
Frey TR; Brathwaite J; Li X; Burgula S; Akinyemi IA; Agarwal S; Burton EM; Ljungman M; McIntosh MT; Bhaduri-McIntosh S
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941784
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis.
Li H; Liu S; Hu J; Luo X; Li N; M Bode A; Cao Y
Int J Biol Sci; 2016; 12(11):1309-1318. PubMed ID: 27877083
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic Activation of Lytic Epstein-Barr Virus Gene Expression without Virion Production.
Lee J; Kosowicz JG; Hayward SD; Desai P; Stone J; Lee JM; Liu JO; Ambinder RF
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341058
[TBL] [Abstract][Full Text] [Related]
7. A Screen for Epstein-Barr Virus Proteins That Inhibit the DNA Damage Response Reveals a Novel Histone Binding Protein.
Ho TH; Sitz J; Shen Q; Leblanc-Lacroix A; Campos EI; Borozan I; Marcon E; Greenblatt J; Fradet-Turcotte A; Jin DY; Frappier L
J Virol; 2018 Jul; 92(14):. PubMed ID: 29743367
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus co-opts TFIIH component XPB to specifically activate essential viral lytic promoters.
Verma D; Church TM; Swaminathan S
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):13044-13055. PubMed ID: 32434920
[TBL] [Abstract][Full Text] [Related]
9. Therapies based on targeting Epstein-Barr virus lytic replication for EBV-associated malignancies.
Li H; Hu J; Luo X; Bode AM; Dong Z; Cao Y
Cancer Sci; 2018 Jul; 109(7):2101-2108. PubMed ID: 29751367
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr Virus Infection in Lung Cancer: Insights and Perspectives.
Osorio JC; Blanco R; Corvalán AH; Muñoz JP; Calaf GM; Aguayo F
Pathogens; 2022 Jan; 11(2):. PubMed ID: 35215076
[TBL] [Abstract][Full Text] [Related]
11. Structural Basis for Cooperative Binding of EBNA1 to the Epstein-Barr Virus Dyad Symmetry Minimal Origin of Replication.
Malecka KA; Dheekollu J; Deakyne JS; Wiedmer A; Ramirez UD; Lieberman PM; Messick TE
J Virol; 2019 Oct; 93(20):. PubMed ID: 31142669
[TBL] [Abstract][Full Text] [Related]
12. Secreted Oral Epithelial Cell Membrane Vesicles Induce Epstein-Barr Virus Reactivation in Latently Infected B Cells.
Lin Z; Swan K; Zhang X; Cao S; Brett Z; Drury S; Strong MJ; Fewell C; Puetter A; Wang X; Ferris M; Sullivan DE; Li L; Flemington EK
J Virol; 2016 Jan; 90(7):3469-79. PubMed ID: 26764001
[TBL] [Abstract][Full Text] [Related]
13. EBV Infection and Glucose Metabolism in Nasopharyngeal Carcinoma.
Zhang J; Jia L; Tsang CM; Tsao SW
Adv Exp Med Biol; 2017; 1018():75-90. PubMed ID: 29052133
[TBL] [Abstract][Full Text] [Related]
14. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
[TBL] [Abstract][Full Text] [Related]
15. Cellular STAT3 functions via PCBP2 to restrain Epstein-Barr Virus lytic activation in B lymphocytes.
Koganti S; Clark C; Zhi J; Li X; Chen EI; Chakrabortty S; Hill ER; Bhaduri-McIntosh S
J Virol; 2015 May; 89(9):5002-11. PubMed ID: 25717101
[TBL] [Abstract][Full Text] [Related]
16. Latent Membrane Protein 1 Is a Novel Determinant of Epstein-Barr Virus Genome Persistence and Reactivation.
Caves EA; Butch RM; Cook SA; Wasil LR; Chen C; Di YP; Lee N; Shair KHY
mSphere; 2017; 2(6):. PubMed ID: 29134204
[TBL] [Abstract][Full Text] [Related]
17. Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.
Reusch JA; Nawandar DM; Wright KL; Kenney SC; Mertz JE
J Virol; 2015 Feb; 89(3):1731-43. PubMed ID: 25410866
[TBL] [Abstract][Full Text] [Related]
18. Lytic viral replication as a contributor to the detection of Epstein-Barr virus in breast cancer.
Huang J; Chen H; Hutt-Fletcher L; Ambinder RF; Hayward SD
J Virol; 2003 Dec; 77(24):13267-74. PubMed ID: 14645583
[TBL] [Abstract][Full Text] [Related]
19. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
[TBL] [Abstract][Full Text] [Related]
20. Niclosamide inhibits lytic replication of Epstein-Barr virus by disrupting mTOR activation.
Huang L; Yang M; Yuan Y; Li X; Kuang E
Antiviral Res; 2017 Feb; 138():68-78. PubMed ID: 27939840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
